All News

acr_session2.jpeg

ACR 2025 - Day 3 Report

d Jack Cush, MD

Day 3 in Chicago is hump day, the last big full day of presentations and posters.  The day began with an 8AM plenary session, which brings me to the first of my three notables from today:

Read Article
pro con unsure opinion thumbs debate

The Great Debate – Who Really Won?

d Michael Putman, MD, MSCI

My favorite session at ACR Convergence is often the “Great Debate.” The debate this year also evaluated one of my favorite topics – ultrasound in giant cell arteritis (GCA). More specifically, it asked the question of whether biopsy or ultrasound should be the preferred modality for diagnosing GCA.

Read Article
microbiome,blue

Microbiome may hold key to methotrexate response in RA

d Mrinalini Dey, MD

Methotrexate (MTX) remains the cornerstone of rheumatoid arthritis (RA) treatment, yet it remains unclear as to how to predict who will respond to it. Two studies presented at ACR (Abstracts 2639 and 2643) suggest the answer may be hiding in the gut.

Read Article
ACRmtg.jpg (keep)

ACR25 Best Abstracts - Day 3

d Jack Cush, MD

Tweeting about an ACR presentation or poster is a skill and sometimes art -- one that is mastered by the RheumNow faculty roving the halls and floors for the best new insights at ACR Convergence 2025.

Read Article
older woman with clasped hands

Accelerated Aging in Rheumatic Disease: From Biology to Lifestyle Intervention

d Jiha Lee, MD

At ACR 2025, the session “27M02: Nutrition for Rheumatic Disease: Where Aging Biology, Sarcopenia, and Diet Intersect” invited the audience to view rheumatic disease through the lens of biological aging and to consider how nutrition and exercise can serve as integrative lifestyle interventions.

Read Article
#ACR25 Abstr#LB15 Tell #RA patients on methotrexate that eating high fibre diet is good for them! An RCT showed improved EULAR response vs PBO. Likely due to restoration of Th17/Treg balance @RheumNow https://t.co/NbwQFqJNho

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)

#ACR25 Abstr#LB14 Promising therapy BMS-986353, a CD19 CAR-T in Severe Refractory Idiopathic Inflammatory Myopathies. 11/12 had evaluable data; muscle, skin and ILD improved. 1 x G2 CRS, 1 G3 ICANS. Longer FU needed and larger sample @RheumNow https://t.co/zAG23tAsbL

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#ACR25 Abstr#2411 How good is performance of 2019 ACR-EULAR #SLE criteria at the point of diagnosis in At-Risk ANA+ people? Our group compared this with Clinician dx -> high specificity(93.8%); low sensitivity(79.3%). Might be a cause why SMILE HCQ RCT failed in At-Risk @RheumNow https://t.co/6GNU2B2wvj

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Cohort study comparing 3yr safety outcomes of JAKi vs. TNFi in AS pts JAKi use: ⬆️incidence of HZ infxn but not significant; ⬆️all-cause mortality (HR 4.94) and GI bleed (p=0.04) Individualize tx. consider potential complications #ACR25 @RheumNow Abs2633 https://t.co/pjKAazQFwW

Links:

sheila RHEUMarampa ( View Tweet)
Sex differences in 💊 d/c in axSpA from the RISE registry 🔅Females - ⬆️discontinuation risks for TNFi 🔅No sex differences seen in dc risks for IL17i and JAKis 🔅Young females discontinued faster than males Gender diff in SpA can guide tx decisions #ACR25 @RheumNow Abs2634 https://t.co/kcXfZrU4zI

Links:

sheila RHEUMarampa ( View Tweet)
Can we catch PsA before it starts? My take on #ABSTRACT0877 for #ACR25 @RheumNow https://t.co/Rw2gJ4XSsz

Links:

Aurelie Najm AurelieRheumo ( View Tweet)

What a conference! Thanks to all those who stopped by! #ACR25 https://t.co/UMAqnPdK4t
Dr. John Cush RheumNow ( View Tweet)
Sleep Apnea in Psoriatic Arthritis – A Wake Up Call Fatigue is one of the most disabling symptoms in psoriatic arthritis (PsA), yet its causes are often underexplored. At #ACR25, Abstract #0549, a possible hidden contributor was studied: obstructive sleep apnea (OSA). In a https://t.co/E3cy1Uss73
Dr. John Cush RheumNow ( View Tweet)
We often see patients with MTX lab abnormalities but How frequent is MTX toxicity? Retrospective study 2500pts Rochester Epidemiology Project cohort 60% w/ ever lab abnormalities, but 4% attributed to MTX 0.87/100 patient year Organ injury event 0.02/100 patient year = 5 in https://t.co/w8oYUjj5Yp

Links:

Aurelie Najm AurelieRheumo ( View Tweet)
Lung Disease in ANCA-associated Vasculitis Dr. Mike Putman discusses abstract 0721, "Pulmonary Manifestations of Granulomatosis with Polyangiitis and Microscopic Polyangiitis", presented at #ACR25. https://t.co/A5uKT4jG1I https://t.co/7E4k7QdiNK

Links:

Dr. John Cush RheumNow ( View Tweet)
ACR2025 Day 3 Recap https://t.co/ZQ1mZePZ1S

Links:

Dr. John Cush RheumNow ( View Tweet)

Disease activity associated with symtomatic knee OA and increased with increased KL grades Abst#2625 #ACR25 @RheumNow https://t.co/uCrdnVXk0J

Links:

Bella Mehta bella_mehta ( View Tweet)
A deep dive into Lupus 🔬 Abstract 2601: Single-cell insights in SLE & pre-clinical autoimmunity 🔹 Plasmablast expansion → high disease activity & SLE risk 🔹 Metabolic activity varies by cell type 🔹 Established disease: ↑ glycolysis & OxPHOS changes @RheumNow #ACR25

Akhil Sood MD, MS AkhilSoodMD ( View Tweet)

Head to head study of Secukinumab vs Ustekinumab. In TNFi-experienced PsA patients, the AgAIN trial shows secukinumab performed better than ustekinumab in HAQ-DI response (57.1% vs 27.0%, p=0.002) and across all endpoints (joint counts, pain, and skin outcomes). Fewer https://t.co/CDCWkLF5TW

Links:

Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Abstract 2360: Single-center lupus pregnancy cohort found that: 🔹 Absence of DORIS remission associated w/ adverse pregnancy outcomes (Pre-term, Pre-eclampsia) 🔹 This is along with known risk factors: antihypertensive use, prior nephritis, active disease @RheumNow #ACR25 https://t.co/STg1NBeFPo

Links:

Akhil Sood MD, MS AkhilSoodMD ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×